Delving into the Latest Updates on MHB039A with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Target-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Minghui Pharmaceutical (Hangzhou) Co., Ltd.Startup

Active Organization

Minghui Pharmaceutical (Hangzhou) Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价MHB039A在晚期恶性实体肿瘤中的安全性及耐受性；次要目的：评价MHB039A在晚期恶性实体肿瘤患者中的药代动力学；评价MHB039A在晚期恶性实体肿瘤患者中的免疫原性；评估MHB039A治疗晚期恶性实体瘤受试者的初步疗效。

[Translation]

Primary objective: To evaluate the safety and tolerability of MHB039A in patients with advanced malignant solid tumors; Secondary objectives: To evaluate the pharmacokinetics of MHB039A in patients with advanced malignant solid tumors; To evaluate the immunogenicity of MHB039A in patients with advanced malignant solid tumors; To evaluate the preliminary efficacy of MHB039A in the treatment of subjects with advanced malignant solid tumors.

Start Date-

Sponsor / Collaborator

Minghui Pharmaceutical (Hangzhou) Co., Ltd.Startup

NCT06345482 / Not yet recruitingPhase 1/2

A Phase I/II Study of MHB039A for Advanced Solid Tumor to Evaluate the Efficacy and Safety

Phase I/II open label, multicenter study to evaluate the efficacy and safety of MHB039A in advanced malignant tumors.

Start Date01 Apr 2024

Sponsor / Collaborator

Minghui Pharmaceutical (Hangzhou) Co., Ltd.Startup

100 Clinical Results associated with MHB039A

Login to view more data

100 Translational Medicine associated with MHB039A